Sanofi Aktie

42,60 EUR +1,20 EUR +2,90 %

23.07.2025

BMN

49,83 USD -0,34 USD -0,68 %

nachbörslich23.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV20,07Div. Rendite3,31%

WKN662283

ISINUS80105N1054

SymbolSNY

Sanofi Aktien News

Sortieren:Datum Meistgelesen

22.07.25PR NewswireBEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study

22.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

17.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

WerbungSanofi-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

07.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

02.07.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

27.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

26.06.25PR NewswireSanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

22.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

17.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

15.06.25GlobeNewswirePress Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-

12.06.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

09.06.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - May 2025

09.06.25PR NewswireSanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

09.06.25GlobeNewswirePress Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

05.06.25GlobeNewswirePress release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

03.06.25GlobeNewswirePress Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

03.06.25GlobeNewswirePress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

02.06.25PR NewswireSanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

02.06.25GlobeNewswirePress Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

30.05.25GlobeNewswirePress Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

29.05.25GlobeNewswirePress Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

27.05.25GlobeNewswirePress Release: Sanofi completes acquisition of DR-0201

22.05.25PR NewswireSanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

22.05.25GlobeNewswirePress Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

15.05.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - April 2025

14.05.25PR NewswireSanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing

02.05.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2025

30.04.25GlobeNewswirePress Release: Annual General Meeting of April 30, 2025

30.04.25GlobeNewswirePress Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

29.04.25GlobeNewswirePress Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

24.04.25GlobeNewswirePress Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

18.04.25GlobeNewswirePress Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

15.04.25PR NewswireChrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

15.04.25GlobeNewswirePress Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

08.04.25GlobeNewswirePress Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

03.04.25GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - February 2025

03.04.25GlobeNewswirePress Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

28.03.25GlobeNewswirePress Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.